Breaking Down Teva Pharmaceutical Indus: 5 Analysts Share Their Views
Portfolio Pulse from Benzinga Insights
Analysts have recently evaluated Teva Pharmaceutical Indus (NYSE:TEVA), with a mix of bullish and somewhat bullish ratings. The average 12-month price target has increased to $21.0 from $18.60. Key analysts from firms like Jefferies, Barclays, B of A Securities, and Piper Sandler have raised their price targets and ratings. Despite positive revenue growth, Teva faces challenges with profitability, return on equity, and debt management.
June 27, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have shown a mix of bullish and somewhat bullish ratings for Teva Pharmaceutical Indus (NYSE:TEVA), with an increased average 12-month price target of $21.0. Key analysts from Jefferies, Barclays, B of A Securities, and Piper Sandler have raised their price targets and ratings. Despite positive revenue growth, Teva faces challenges with profitability, return on equity, and debt management.
The increase in the average price target and the positive ratings from key analysts suggest a bullish short-term impact on TEVA's stock price. However, the company's financial challenges in profitability, return on equity, and debt management may temper the overall positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100